Tempus AI, Inc (TEM)
Market Cap | 9.26B |
Revenue (ttm) | 640.44M |
Net Income (ttm) | -800.71M |
Shares Out | 157.45M |
EPS (ttm) | -8.52 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 555,693 |
Open | 62.47 |
Previous Close | 62.94 |
Day's Range | 58.16 - 62.47 |
52-Week Range | 22.89 - 79.49 |
Beta | n/a |
Analysts | Buy |
Price Target | 55.00 (-6.51%) |
Earnings Date | Nov 4, 2024 |
About TEM
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to ph... [Read more]
Financial Performance
In 2023, Tempus AI's revenue was $531.82 million, an increase of 65.85% compared to the previous year's $320.67 million. Losses were -$265.96 million, -20.35% less than in 2022.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $55.0, which is a decrease of -6.51% from the latest price.
News
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annu...
The Big 3: CRWD, CVNA, TEM
@ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatilit...
Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecul...
Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR®
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron...
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Acti...
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer...
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted fo...
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immu...
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...
Tempus to Report Third Quarter 2024 Financial Results on November 4
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday,...
Tempus and Northwestern Medicine Announce Collaboration to Bring Practical Application of AI to Healthcare
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago's premier integrated academic health system, today announced a collabor...
Tempus: Attempting To Lead The AI Revolution In Healthcare
Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutio...
Tempus to Report Third Quarter 2024 Financial Results on November 7
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursda...
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaborati...
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted fo...
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-fa...
Tempus Announces Real World Data Collaboration with BioNTech
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collabor...
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Ann...
Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +
In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted...
Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad ...
Cathie Wood bets big on Tempus AI: Is it the next big thing in health-tech?
Cathie Wood, a prominent advocate for innovative technologies, is making a bold bet on artificial intelligence with her latest investment in Tempus AI Inc. (NASDAQ: TEM). Known for her strategic focu...
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
BERGEN, Norway , Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, ...
Tempus AI Soars To New Highs, Investments From Google And SoftBank Boost Bullish Sentiment
Tempus AI Inc. TEM, a cutting-edge healthcare diagnostics company, has been on a tear. The stock established a new high of $47.81 on Thursday.
Personalis and Tempus Announce Expanded Collaboration
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed...
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of it...